Literature DB >> 20216380

Impact of tumor response on survival after radiochemotherapy in locally advanced rectal carcinoma.

Anne Rullier1, Christophe Laurent, Maylis Capdepont, Véronique Vendrely, Paulette Bioulac-Sage, Eric Rullier.   

Abstract

In locally advanced rectal adenocarcinoma, preoperative radiochemotherapy induces tumor response. The impact of pathologic tumor response on survival is still debated because of the numerous distinct tumor-response gradings available in the literature and the lack of standardized pathologic approach. The objective of this work was to study the impact of tumor response on survival, according to the 4 main tumor-response gradings available in the literature in locally advanced rectal adenocarcinoma after preoperative radiochemotherapy. From 1995 to 2004, 292 consecutive patients with cT3-T4 and/or N+ rectal adenocarcinoma were enrolled. Tumor response was evaluated according to ypTN-response gradings (downstaging: ypT0-2 N0 and complete pathologic response: ypT0 N0) and cellular-response gradings (ie, Mandard et al's and Rodel et al's gradings). The impact of tumor-response gradings and of different clinicopathologic variables on 5-year disease-free and overall survival were studied by univariate and multivariate analyses. We found that all tumor-response gradings were associated with survival. However, multivariate analysis showed that downstaging was the only tumor-response grading that influenced survival independently. In the subgroup of stage II patients (n=99), we also observed no difference on both 5-year disease-free and overall survival between low and high responders according to cellular response. In conclusion, in our experience, downstaging is the only tumor-response grading that influenced survival independently in locally advanced rectal adenocarcinomas. Cellular-response gradings had no impact on survival even in stage II patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20216380     DOI: 10.1097/PAS.0b013e3181d438b0

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

Review 1.  Neoadjuvant vs adjuvant pelvic radiotherapy for locally advanced rectal cancer: Which is superior?

Authors:  Sarah Popek; Vassiliki Liana Tsikitis
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

2.  Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy.

Authors:  Daniel Delitto; Thomas J George; Tyler J Loftus; Peihua Qiu; George J Chang; Carmen J Allegra; William A Hall; Steven J Hughes; Sanda A Tan; Christiana M Shaw; Atif Iqbal
Journal:  J Natl Cancer Inst       Date:  2018-05-01       Impact factor: 13.506

3.  One-level step section histological analysis is insufficient to confirm complete pathological response after neoadjuvant chemoradiation for rectal cancer.

Authors:  M A Pereira; A R Dias; S F Faraj; C S R Nahas; A R Imperiale; C F S Marques; G C Cotti; B C Azevedo; S C Nahas; E S de Mello; U Ribeiro
Journal:  Tech Coloproctol       Date:  2017-08-17       Impact factor: 3.781

4.  Prognostic value of tumor shrinkage versus fragmentation following radiochemotherapy and surgery for rectal cancer.

Authors:  Monirath Hav; Louis Libbrecht; Karen Geboes; Liesbeth Ferdinande; Tom Boterberg; Wim Ceelen; Piet Pattyn; Claude Cuvelier
Journal:  Virchows Arch       Date:  2015-02-19       Impact factor: 4.064

5.  A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer.

Authors:  Chin-Fan Chen; Ming-Yii Huang; Chih-Jen Huang; Chan-Han Wu; Yung-Sung Yeh; Hsiang-Lin Tsai; Cheng-Jen Ma; Chien-Yu Lu; Shun-Jen Chang; Ming-Jenn Chen; Jaw-Yuan Wang
Journal:  Int J Colorectal Dis       Date:  2012-01-19       Impact factor: 2.571

6.  A prognostic nomogram for stage II/III rectal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgical resection.

Authors:  Yanfei Lin
Journal:  BMC Surg       Date:  2022-07-04       Impact factor: 2.030

7.  What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy?

Authors:  Soo Hee Kim; Hee Jin Chang; Dae Yong Kim; Ji Won Park; Ji Yeon Baek; Sun Young Kim; Sung Chan Park; Jae Hwan Oh; Ami Yu; Byung-Ho Nam
Journal:  Cancer Res Treat       Date:  2015-10-22       Impact factor: 4.679

Review 8.  Pathologic Assessment of Rectal Carcinoma after Neoadjuvant Radio(chemo)therapy: Prognostic Implications.

Authors:  Monirath Hav; Louis Libbrecht; Liesbeth Ferdinande; Karen Geboes; Piet Pattyn; Claude A Cuvelier
Journal:  Biomed Res Int       Date:  2015-10-05       Impact factor: 3.411

9.  Comparison between preoperative and postoperative concurrent chemoradiotherapy for rectal cancer: an institutional analysis.

Authors:  Jeong Won Lee; Jong Hoon Lee; Jun-Gi Kim; Seong Taek Oh; Hyuk Jun Chung; Myung Ah Lee; Hoo Geun Chun; Song Mi Jeong; Sei Chul Yoon; Hong Seok Jang
Journal:  Radiat Oncol J       Date:  2013-09-30

10.  Tumor regression grades: can they influence rectal cancer therapy decision tree?

Authors:  Marisa D Santos; Cristina Silva; Anabela Rocha; Eduarda Matos; Carlos Nogueira; Carlos Lopes
Journal:  Int J Surg Oncol       Date:  2013-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.